<DOC>
	<DOCNO>NCT00883779</DOCNO>
	<brief_summary>This 2 arm study compare efficacy safety sequential treatment Tarceva placebo , plus platinum-based therapy , first line treatment patient advanced recurrent non-small cell lung cancer . Patients randomize receive gemcitabine ( 1250mg/m2 iv ) day 1 8 , cisplatin ( 75mg/m2 ) carboplatin ( 5xAUC ) day 1 , follow Tarceva 150mg/day placebo day 15 day 28 4 week cycle total 6 cycle , follow Tarceva placebo monotherapy.The anticipated time study treatment disease progression , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Tarceva ( Erlotinib ) Placebo Combination With Platinum-Based Therapy First Line Treatment Patients With Advanced Recurrent Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; advance ( stage IIIB/IV ) nonsmall cell lung cancer ; measurable disease ; Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1. prior exposure agent direct HER axis ; prior chemotherapy systemic antitumor therapy advance disease ; unstable systemic disease ; malignancy within last 5 year , except cure basal cell cancer skin cure cancer situ cervix ; brain metastasis spinal cord compression .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>